当前位置: 首页 >> 检索结果
3321. Low-energy endocardial defibrillation using an axillary or a pectoral thoracic electrode location.
A significant proportion of patients receiving endocardial defibrillation lead systems must accept either high defibrillation thresholds (DFTs) with lower safety margins or lead implantation by thoracotomy. We examined the feasibility of achieving universal application of endocardial leads and lower defibrillation energy requirements by optimizing the lead system location in conjunction with biphasic shocks.
3322. Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-blind, randomized, placebo-controlled trial.
作者: G Melandri.;F Semprini.;V Cervi.;N Candiotti.;E Palazzini.;A Branzi.;B Magnani.
来源: Circulation. 1993年88卷6期2517-23页
Patients with chronic coronary artery disease exhibit a dysfunctioning endothelium, which may be responsible for exercise-induced platelet activation and expression of a procoagulant moiety. In this study, we evaluated the therapeutic efficacy of a low molecular weight heparin (Parnaparin) in patients with stable angina pectoris.
3323. Factors influencing 1-year patency of coronary artery saphenous vein grafts. Studio Indobufene nel Bypass Aortocoronarico (SINBA).
作者: G Cataldo.;M Braga.;N Pirotta.;M Lavezzari.;F Rovelli.;E Marubini.
来源: Circulation. 1993年88卷5 Pt 2期II93-8页
To evaluate the possible influence of a series of clinical angiographic and surgical variables on the 1-year patency of saphenous vein (SV) coronary graft, data collected prospectively in a multicenter randomized clinical trial were analyzed.
3324. Randomized, prospective assessment of bioprosthetic valve durability. Hancock versus Carpentier-Edwards valves.
作者: G E Sarris.;R C Robbins.;D C Miller.;R S Mitchell.;K A Moore.;E B Stinson.;P E Oyer.;B A Reitz.;N E Shumway.
来源: Circulation. 1993年88卷5 Pt 2期II55-64页
Although the major limitation of porcine valves is their finite durability, no controlled clinical data exist regarding the relative durability of the two porcine bioprostheses implanted most commonly today, the Carpentier-Edwards (C-E) and Medtronic Hancock I (H) valves.
3325. Nafamostat mesilate reduces blood loss during open heart surgery.
Nafamostat mesilate (FUT-175) is a protease inhibitor inactivating coagulation, fibrinolysis, and platelet aggregation. A prospective, randomized trial was performed to assess the efficacy of FUT-175 in the reduction of postoperative bleeding tendency.
3326. Comparison of cold versus warm cardioplegia. Crystalloid antegrade or retrograde blood?
作者: T Z Lajos.;C C Espersen.;P S Lajos.;R C Fiedler.;J Bergsland.;L T Joyce.
来源: Circulation. 1993年88卷5 Pt 2期II344-9页
To evaluate the efficacy of warm versus cold and antegrade versus retrograde cardioplegia, 163 patients were randomized in sequence in three groups and underwent isolated coronary artery bypasses (mean, 4 grafts/patients) alternating in sequence.
3327. Influence of left ventricular assist on valvular regurgitation.
作者: W L Holman.;R C Bourge.;P Fan.;J K Kirklin.;A D Pacifico.;N C Nanda.
来源: Circulation. 1993年88卷5 Pt 2期II309-18页
The effects of mechanical left ventricular assist on the nonassisted right ventricle have not been fully elucidated. Current information indicates that the right ventricle benefits from a lower left atrial pressure; however, ventricular septal shifting and increased venous return caused by left ventricular assist impair right ventricular function. Acute intraoperative alterations in mitral and tricuspid valve regurgitation (MR and TR, respectively) may occur as a result of mechanical left ventricular assist but have not yet been documented.
3328. Cyclosporine-induced hypertension. Efficacy of omega-3 fatty acids in patients after cardiac transplantation.
作者: H O Ventura.;R V Milani.;C J Lavie.;F W Smart.;D D Stapleton.;T S Toups.;H L Price.
来源: Circulation. 1993年88卷5 Pt 2期II281-5页
Cyclosporine-induced hypertension may be related to vasoconstriction of the afferent arterioles in the glomeruli caused by changes in the prostaglandin profile. omega-3 Fatty acids have demonstrated vasodilatory properties related to a favorable effect in the prostaglandin profile. The purpose of this study was to evaluate the antihypertensive effects of oral supplementation with omega-3 fatty acids in cyclosporine-treated cardiac transplant recipients.
3329. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators.
作者: M A Konstam.;M W Kronenberg.;M F Rousseau.;J E Udelson.;J Melin.;D Stewart.;N Dolan.;T R Edens.;S Ahn.;D Kinan.
来源: Circulation. 1993年88卷5 Pt 1期2277-83页
Patients with heart failure and reduced left ventricular (LV) ejection fraction (EF) manifest progressive LV dilatation, which is prevented by angiotensin converting enzyme (ACE) inhibitors. In patients with asymptomatic LV systolic dysfunction, in whom there is less activation of the renin-angiotensin system, ventricular remodeling might be less rapid and the benefit of ACE inhibitors less discernible.
3330. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty.
作者: A A van den Bos.;J W Deckers.;G R Heyndrickx.;G J Laarman.;H Suryapranata.;F Zijlstra.;P Close.;J J Rijnierse.;H R Buller.;P W Serruys.
来源: Circulation. 1993年88卷5 Pt 1期2058-66页
Enhanced thrombin activity has been associated with acute and long-term complications following balloon angioplasty (percutaneous transluminal coronary angioplasty (PTCA). We evaluated, in a 2-to-1 randomized, double-blind trial, the effects of recombinant hirudin, CGP 39 393, relative to unfractionated sodium heparin on periprocedural events, bleeding, early angiographic outcome, and coagulation in 113 patients with stable angina undergoing PTCA.
3331. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina.
作者: P Théroux.;D Waters.;S Qiu.;J McCans.;P de Guise.;M Juneau.
来源: Circulation. 1993年88卷5 Pt 1期2045-8页
Antiplatelet therapy with aspirin and antithrombotic therapy with heparin both prevent the complications of unstable angina; however, no definitive data exist on the relative clinical efficacy of the two drugs.
3332. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure.
作者: S S Gottlieb.;K Dickstein.;E Fleck.;J Kostis.;T B Levine.;T LeJemtel.;M DeKock.
来源: Circulation. 1993年88卷4 Pt 1期1602-9页
Losartan is a new specific angiotensin II receptor antagonist with no agonist properties that provides the opportunity to study the consequences of angiotensin II blockade. The objective of the present study was to evaluate the hemodynamic and neurohormonal response to losartan in patients with congestive heart failure.
3333. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
作者: P W Serruys.;W Klein.;J P Tijssen.;W Rutsch.;G R Heyndrickx.;H Emanuelsson.;S G Ball.;O Decoster.;E Schroeder.;H Liberman.
来源: Circulation. 1993年88卷4 Pt 1期1588-601页
Ketanserin is a serotonin S2-receptor antagonist that inhibits the platelet activation and vasoconstriction induced by serotonin and also inhibits the mitogenic effect of serotonin on vascular smooth muscle cells.
3334. Race and prognosis after myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
作者: H A Taylor.;B R Chaitman.;W J Rogers.;M J Kern.;M L Terrin.;F V Aguirre.;G Sopko.;R McMahon.;R N Ross.;E C Bovill.
来源: Circulation. 1993年88卷4 Pt 1期1484-94页
To better understand the role of race/ethnicity in survival after acute myocardial infarction, we compared clinical and laboratory data, response to thrombolytic therapy, and clinical outcome in 2885 patients participating in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Trial among three groups of patients (2564 whites, 174 blacks, and 147 Hispanics).
3335. Height and incidence of cardiovascular disease in male physicians.
作者: P R Hebert.;J W Rich-Edwards.;J E Manson.;P M Ridker.;N R Cook.;G T O'Connor.;J E Buring.;C H Hennekens.
来源: Circulation. 1993年88卷4 Pt 1期1437-43页
An inverse association between height and risk of coronary heart disease (CHD) has been reported in several case-control and cohort studies, but the reasons for the association remain uncertain. We evaluated this association among 22,071 male physicians, a population homogeneous for high educational attainment and socioeconomic status in adulthood.
3336. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group.
作者: B J Rensing.;W R Hermans.;J Vos.;J G Tijssen.;W Rutch.;N Danchin.;G R Heyndrickx.;E G Mast.;W Wijns.;P W Serruys.
来源: Circulation. 1993年88卷3期975-85页
The renarrowing process after successful percutaneous transluminal coronary angioplasty (PTCA) is now believed to be caused by a response-to-injury vessel wall reaction. The magnitude of this process can be assessed by the change in minimal lumen diameter (MLD) at follow-up angiography. The aim of the present study was to find independent patient-related, lesion-related, and procedure-related risk factors for this luminal narrowing process. A model that accurately predicts the amount of luminal narrowing could be an aid in patient or lesion selection for the procedure, and it could improve assessment of medium-term (6 months) prognosis. Modification or control of the identified risk factors could reduce overall restenosis rates, and it could assist in the selection of patients at risk for a large loss in lumen diameter. This population could then constitute the target population for pharmacological intervention studies.
3337. Bamiphylline improves exercise-induced myocardial ischemia through a novel mechanism of action.
作者: A Gaspardone.;F Crea.;M Iamele.;F Tomai.;F Versaci.;A Pellegrino.;L Chiariello.;P A Gioffré.
来源: Circulation. 1993年88卷2期502-8页
In patients with stable angina pectoris aminophylline, a nonselective antagonist of adenosine receptors, markedly improves exercise capacity. To establish the role played by A1 adenosine receptors in the anti-ischemic action of aminophylline, the effects of bamiphylline, a selective A1 antagonist, on exercise-induced ischemia were investigated in patients with stable angina pectoris.
3338. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
作者: B M Massie.;M R Berk.;S C Brozena.;U Elkayam.;J F Plehn.;M L Kukin.;M Packer.;B E Murphy.;G W Neuberg.;R M Steingart.
来源: Circulation. 1993年88卷2期492-501页
Angiotensin converting enzyme inhibitors, diuretics, and digoxin are each effective in treating congestive heart failure, but many patients remain symptom-limited on all three medications. This trial was designed to determine whether the addition of oral flosequinan, a new direct-acting arterial and venous vasodilator with possible dose-dependent positive inotropic effects, improves exercise tolerance and quality of life in such patients.
3339. Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis.
作者: A Kornberg.;C W Francis.;V D Pellegrini.;K R Gabriel.;V J Marder.
来源: Circulation. 1993年88卷2期454-60页
Oral anticoagulation is most frequently monitored using the prothrombin time, but an alternative approach is measurement of native, fully carboxylated, prothrombin antigen (NPA). We have correlated results of the prothrombin time and NPA with development of venous thrombosis or bleeding complications in a clinical trial of warfarin prophylaxis following total hip arthroplasty to determine the potential value of NPA measurement for monitoring oral anticoagulation.
3340. Low doses of scopolamine increase cardiac vagal tone in the acute phase of myocardial infarction.
Reduced cardiac vagal tone in patients with myocardial infarction (MI) is associated with a high risk of sudden death. Muscarinic blocking agents in small doses induce a paradoxical increase in cardiac vagal activity in normal subjects. We tested whether low doses of scopolamine delivered transdermally enhance tonic and reflex cardiac vagal activity in patients in the acute phase of MI.
|